Business US
GSK to acquire Nuvalent and its two cancer drugs under FDA review for $10.6B – Endpoints News
- GSK to acquire Nuvalent and its two cancer drugs under FDA review for $10.6B Endpoints News
- Nuvalent shares surge 39% after UK’s GSK agrees to buy the cancer drugmaker for $10.6 billion CNBC
- New GSK CEO’s Cancer Deal Signals Bigger Ambitions WSJ
- GSK enters agreement to acquire Nuvalent, Inc. GSK
- GSK pays $10.6B for cancer biotech Nuvalent in industry’s second-biggest buy of the year BioSpace
